In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs.

ABSTRACT: Coronavirus disease (COVID-19) is an emerging pandemic that threatens the world since the early days of 2020. Development of vaccines or new drugs against COVID-19 comprises several stages of investigation including efficacy, safety, and approval studies. A shortcut to this delicate pathway is computational-based analysis of FDA-approved drugs against assigned molecular targets of the coronavirus. In this study, we virtually screened a library of FDA-approved drugs prescribed for different therapeutic purposes against versatile COVID-19 specific proteins which are crucial for the virus life cycle. Three antibiotics in our screening polymyxin B, bafilomycin A, and rifampicin show motivating binding stability with more than one target of the virus. Another category of tested drugs is oral an

SUBMITTER: Elmorsy MA 

PROVIDER: S-EPMC8475441 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature